CFDA To Outsource Drug Reviews

July 26, 2014 --The CFDA will begin outsourcing reviews for drug approvals to speed up the process and consider a priority review system for important new generics; Skystar Bio-Pharma, a Xi’an veterinary medicine company, raised $5 million for acquisitions and in-licensing; Welichem Biotech of Canada ended its attempt to buy back China rights to a topical psoriasis treatment; CASI Pharma of the US received CFDA permission to start a China Phase II trial of a novel cancer drug; Berry Genomics, a Beijing company, is seeking CFDA approval for its noninvasive prenatal test; Merck KGaA will break ground in August on its new $108 million Shanghai manufacturing plant; BGI Tech Solutions launched a human whole exome sequencing service at a cost of $599 per sample; and China Cord Blood will cooperate with Singapore’s Cordlife Group to find suitable donors in each other’s umbilical cord blood stem cell banks.

Help employers find you! Check out all the jobs and post your resume.